Guiding the attack: CXCR3 leads CAR T cells to pediatric brain tumors

Jan 13

1 min read

CAR T cell therapies targeting B7-H3 (CD276), a marker expressed on DIPG tumors, have been tested in early phase clinical trials and demonstrated feasibility and tolerability. [...] However, many CAR T cells may struggle to travel into the tumor and exert their cancer-killing effects.

Comments

Unexpected discovery points to a possible route for childhood brain tumor treatments

Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections

Removing immune 'brake' improves CAR T-cell therapy for pediatric bone cancer

Cardiometabolic Risk in Childhood Cancer Survivors Treated With Anthracyclines

Hodgkin Lymphoma Survivors Face Higher Long-Term Mortality

Emotional health supports physical health in survivors of childhood cancer

Hidden aggressive cells reveal why some lower-risk childhood cancers turn deadly

Personalized T-cell therapy eliminates detectable metastatic kidney tumor in adolescent after multiple relapses

Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends

MBNL1 was identified as a potential cancer drug target for a type of childhood leukemia

Recent Posts